These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26916354)

  • 41. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.
    Chen YH; Huang CN; Cho YM; Li P; Gu L; Wang F; Yang J; Wang WQ
    Diabetes Obes Metab; 2018 Sep; 20(9):2121-2130. PubMed ID: 29708650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
    Umpierrez G; Tofé Povedano S; Pérez Manghi F; Shurzinske L; Pechtner V
    Diabetes Care; 2014 Aug; 37(8):2168-76. PubMed ID: 24842985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.
    Umpierrez GE; Pantalone KM; Kwan AY; Zimmermann AG; Zhang N; Fernández Landó L
    Diabetes Obes Metab; 2016 Jun; 18(6):615-22. PubMed ID: 26969812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.
    Pantalone KM; Patel H; Yu M; Fernández Landó L
    Diabetes Obes Metab; 2018 Jun; 20(6):1461-1469. PubMed ID: 29430801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.
    Grunberger G; Forst T; Fernández Landó L; Pechtner V; Shaginian R; Jia N; Gough S
    Diabet Med; 2016 Mar; 33(3):391-4. PubMed ID: 26179454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes.
    Matza LS; Boye KS; Currie BM; Paczkowski R; Lando LF; Mody R; Jordan J
    Curr Med Res Opin; 2018 Aug; 34(8):1457-1464. PubMed ID: 29661026
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Patel D
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GLP-1 Agonists in Type 1 Diabetes Mellitus.
    Janzen KM; Steuber TD; Nisly SA
    Ann Pharmacother; 2016 Aug; 50(8):656-65. PubMed ID: 27252246
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Goldman JD
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up.
    Li H; Xu X; Wang J; Kong X; Chen M; Jing T; Zhang Z; Yin G; Liu X; Hu Y; Ye L; Su X; Ma J
    J Diabetes Res; 2019; 2019():6423987. PubMed ID: 31183384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
    Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
    Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ACP Journal Club: in metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels.
    Morey-Vargas OL; Shah P
    Ann Intern Med; 2014 Nov; 161(10):JC9. PubMed ID: 25402542
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
    Kuchay MS; Krishan S; Mishra SK; Choudhary NS; Singh MK; Wasir JS; Kaur P; Gill HK; Bano T; Farooqui KJ; Mithal A
    Diabetologia; 2020 Nov; 63(11):2434-2445. PubMed ID: 32865597
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
    Matfin G; Van Brunt K; Zimmermann AG; Threlkeld R; Ignaut DA
    J Diabetes Sci Technol; 2015 Apr; 9(5):1071-9. PubMed ID: 25901022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost Effectiveness of Dulaglutide Compared with Liraglutide and Glargine in Type 2 Diabetes Mellitus Patients in Colombia.
    Lasalvia P; Baquero L; Otálora-Esteban M; Castañeda-Cardona C; Rosselli D
    Value Health Reg Issues; 2017 Dec; 14():35-40. PubMed ID: 29254540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m
    Dilla T; Alexiou D; Chatzitheofilou I; Ayyub R; Lowin J; Norrbacka K
    J Med Econ; 2017 May; 20(5):443-452. PubMed ID: 28008768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
    Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC
    Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.